Hypothesis: We hypothesize that the severity of hearing loss (HL) associated with sporadic vestibular schwannomas (VS) is correlated with tumor secretion of proteins with ototoxic or otoprotective potential. Background: Because the recognition that HL associated with VS is not solely due to compression of the auditory nerve, elucidating the mechanism by which VS cause HL has been an important task. We previously showed that VS stratified by hearing have differential gene expression. We now focus on identifying differentially expressed proteins in tumor secretions. Methods: Fresh surgical specimens of VS were incubated in sterile PBS at 37-C to collect secretions. The specimens were divided into a group associated with good hearing (GH, word recognition Q70% and pure-tone average e30 dB, n = 11) or poor hearing (PH, n = 10). The groups were compared using a customized cytokine array. Statistically significant results were verified with an enzyme-linked immunosorbent assay on a different set of secretions (n = 8 for GH and n = 10 for PH group). Results: Of the 37 molecules we studied, 9 were significantly expressed in secretions from VS compared with secretions from control nerves. Secretion of fibroblast growth factor 2 (FGF2) was 3.5-fold higher in VS associated with GH versus PH based on cytokine array analysis (p = 0.02), which was validated with enzyme-linked immunosorbent assay. Conclusion: This study highlights FGF2, a mitogen known to protect the auditory nerve, as a potential tumor-secreted mediator of hearing protection in VS. If FGF2's significant role in hearing protection in patients with VS is validated, then FGF2 could be used as a biomarker for HL in VS, and therapeutic targeting of the FGF2 signaling pathway may reduce HL due to VS. Key Words: Acoustic neuromaV Cytokine arrayVFGF2VHearing lossVSporadic vestibular schwannoma. Otol Neurotol 34:748Y754, 2013.
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Sporadic vestibular schwannomas (VS), also known as acoustic neuromas, are the most common tumors of the cerebellopontine angle and frequently present with hearing loss (HL) (1) . The pathophysiology of this HL remains elusive. Because VS typically arise from the schwann cells of the vestibular part of the VIIIth cranial nerve, it is commonly assumed that they cause HL by compressing the adjacent auditory portion of the nerve. However, the poor correlation between VS radiologic dimensions and degree of HL suggests that nerve compression is not the only cause of HL due to VS (2) . Furthermore, a retrospective study of patients with intracanalicular VS found no relation between hearing and tumor size or the tumor-induced expansion of the internal auditory canal, reinforcing that nerve compression is not the only modulator of HL (3). However, tumor presence does lead to cochlear degeneration and neuronal loss in patients with VS (4). Previous work from our laboratory demonstrated that VS stratified by hearing into good versus poor hearing groups have distinctly different gene expression profiles, suggesting that differential expression of potentially ototoxic or otoprotective molecules may contribute to the degree of HL associated with VS (5). To gain further insight into the mechanisms of HL, the current study focuses on tumor-secreted factors that may contribute to HL or hearing protection in patients with VS.
We have focused on cytokinesVsmall, secreted cell signaling moleculesVbecause they are thought to mediate HL in a variety of diseases, including meningitis, cochlear otosclerosis and labyrinthitis (6, 7) . Specifically, inhibition of proinflammatory cytokines through molecules, such as interleukin-1 receptor antagonist (IL1RN), has been proposed as potential treatments against presbycusis and other types of sensorineural HL (8, 9) . Additionally, corticosteroids, drugs that are known to repress cytokine gene transcription, are known to be effective in many cases of sudden sensorineural HL associated with VS, suggesting a biochemical imbalance or inflammatory response as a potential trigger for loss of hearing (10Y12).
In addition to cytokines, we studied expression of several nonsecreted molecules in incubated medium from VS because tumors are known to shed (13, 14) . For example, shedding plasma membrane fragments may have proteins attached, including receptors, that can contribute to intercellular signaling (15) . We also studied several candidate molecules identified in our recent proteomic analysis of perilymph from patients with VS (16) . We investigated a total of 37 proteins using a customized cytokine array. Differential expression was validated with enzyme-linked immunosorbent assays (ELISA). Given FGF2's otoprotective role in other contexts, our results point to FGF2 as a secreted molecule (17) that may contribute to hearing protection in some patients with VS (18, 19) .
MATERIALS AND METHODS

Study Population and Specimen Collection
Surgical VS specimens were collected as previously described (5) from a total of 16 adults with good hearing (GH) and 19 adults with poor hearing (PH). Subject demographics are listed in Supplemental Table 1 (http://links.lww.com/MAO/A140). Specimens of healthy great auricular nerves (GAN) were collected from 7 adults undergoing unrelated neck dissections. Specimens were placed in sterile saline on ice for 15 minutes while being transported to the laboratory. Specimens were handled according to the institutional review board's study protocol approved by the Human Studies Committee of Massachusetts General Hospital (Protocol No. 2004-P2297/2, PI: K.M.S) and Massachusetts Eye and Ear Infirmary (Protocol No. 05-02-009X, PI: K.M.S) and in accordance with the Helsinki Declaration. Age was defined at the time of diagnosis. Tumor size (largest diameter parallel to the petrous face), word discrimination (WD), and pure tone average (PTA) were the last measurements before tumor surgery. Tumor growth rate was derived from transverse or greatest dimension measurement changes in serial MRI scans. Informed consent was obtained from all subjects.
Cytokine Array
Fresh human specimens were thoroughly washed in sterile phosphate-buffered saline (PBS) 3 times before being incubated in 500 KL sterile PBS at 37-C for 1 hour. The specimens were then removed from PBS and the tumor-conditioned PBS was stored at j80-C until further use. The same procedure was followed for the VS and GAN specimens. Sterile PBS without specimen was incubated in parallel as a negative control.
Human cytokine array membranes coated with 37 specific antibodies (RayBioTM Human Cytokine Antibody Array, RayBiotech, Inc.) were probed with 21 VS secretion samples, 7 GAN secretion samples, and 1 blank sterile PBS. Antibodies to 6 targets of particular interest because of our past work were shipped to the company for inclusion on the array: Mu-crystallin homolog ( Table 2 , (http://links.lww.com/MAO/A141). The manufacturer's protocol was followed for experimental procedures and data analysis. Samples were dialyzed twice with PBS, pH 8.
Protein concentrations of the dialyzed samples were measured spectrophotometrically and normalized through dilution in sterile PBS before incubation on the array membranes. Cytokine arrays were processed using standard manufacturer's protocol. Briefly, the membranes were exposed to the blocking buffer at room temperature (RT) for 1 hour, incubated with sample at 4-C overnight, washed with Wash Buffer I and II at RT, incubated with biotin-conjugated antibodies at 4-C overnight, and washed and incubated with HRP-conjugated streptavidin at RT for 1 hour. The membranes were incubated in detection buffer for 1 minute and exposed in Chemidoc (BioRad Laboratories, Hercules, CA, USA) for 175 to 350 seconds to obtain a strong, clear signal. The relative expression levels were compared after a densitometric analysis using Quantity One (BioRad Laboratories). Probing with blank PBS treated in the same manner as the samples did not produce positive staining except at the positive control spots coated with the biotinylated IgGs. Proteins were determined to be significantly expressed if the corresponding spots had optical densities more than 2 standard deviations of background values above the mean background level for each array. Statistical significance was determined through an analysis of variance (ANOVA) with alpha set to 0.05.
Enzyme-linked Immunosorbent Assays
ELISA was conducted to validate the result obtained in cytokine array analysis. Tumor samples were collected and incubated in PBS as described previously. A total of 8 VS secretions associated with GH and 10 VS secretions associated with PH were used. Majority of the samples were from different patients than the samples studied in the cytokine array; 4 samples (3 GH and 1 BH samples) overlapped with the cytokine array sample group and are marked with double asterisks in Supplemental 
RESULTS
Tumors associated with GH significantly differed from those associated with PH in pure tone average (PTA) (p G 0.001) and word discrimination (WD) scores (p G 0.001) of the ipsilateral ear but not with respect to age (p = 0.70), sex (p = 0.92), tumor size (p = 0.71), PTA (p = 0.25), or WD (p = 0.80) of the contralateral ear ( Fig. 1 and Supplemental Table 1 , http://links.lww.com/MAO/A140, summarizing subject demographics). Of the 37 proteins studied, 9 were significantly expressed in VS secretions compared with GAN controls (Fig. 2) . Of these, 6 demonstrated a trend for higher expression ( Fig. 2A) , and 3 demonstrated a trend for lower expression (Fig. 2B) in the tumors associated with GH versus PH. Two molecules met our criteria for statistically different level of expression between the 2 groups: FGF2 was 3.5-fold higher (p = 0.02), and IL8 was 3.4-fold higher (p = 0.02) in the VS associated with GH versus VS associated with PH (Fig. 3A) . Expression of FGF2 was closely correlated with IL8 expression for any given tumor (R 2 = 0.978) (Fig. 3B) . Results of cytokine array analysis were validated on a different set of tumor secretions using FGF2 and IL8 ELISA. The ELISA kits that we used have been extensively studied in the literature (20Y23). We again found FGF2 at substantially higher levels in secretions associated with good versus poor hearing (p = 0.05). The magnitude of the difference in average expression detected was higher with ELISA (5.8-fold change) (Fig. 4) in comparison to the cytokine array, possibly because of the greater sensitivity of the antibody used in ELISA versus the proprietary antibody in the cytokine array or because of biological differences in tumor samples.
The IL8 ELISA showed no IL8 expression in VS secretions. The discrepancy between the IL8 ELISA and the cytokine array results is likely because of cross-reactivity between IL8 and FGF2 on the cytokine array. Their highly correlated expression on the cytokine array (Fig. 3B ) suggests a technical artifact as the cytokine array was manufactured with an IL8 antibody that was not tested for cross-reactivity with FGF2. In contrast, the IL8 antibody in the ELISA kit was found to have no significant crossreactivity with FGF2 by the manufacturer.
Of the 9 molecules significantly expressed in VS (Fig. 2) , most are known to be secreted. However, 3 molecules are typically not secreted (CRYAB, ERBB2, and NF2), and their presence in tumor secretions is consistent with shedding (13Y15).
DISCUSSION
A comparative screening of 37 molecules in VS associated with good versus poor hearing identified FGF2 as a potential mediator of hearing protection in VS. The result was robust between the 2 different techniques applied to different samples despite the large intersample variability typically observed in human samples. Nine targets were found to be significantly present in the VS secretions relative to GAN. Some of these targets (CRYAB, NF2, ERBB2, PDGFA, PDGFB, and FGF2) were previously studied in pathophysiology of VS (16,24Y28) . Fibroblast growth factor 2 is a known mitogen for proliferation of VS (29) , but it has not been previously studied in the context of HL because of VS. Increased levels of FGF2 in tumors associated with GH suggest that FGF2 secreted by the tumors may mediate hearing protection. This conjecture is intriguing because of FGF2's known role in protection of the auditory neurons and hair cells from acoustic trauma, glutamate toxicity, and aminoglycoside ototoxicity (17, 18, 30, 31) . It is possible that FGF2 secreted by VS, or by the cranial nerves surrounding VS, protect the auditory nerve and cochlea from damage and death caused by various mechanisms, including nerve compression or structural degradation. VS are known to be associated with substantial degeneration of cochlear structures, including loss of hair cells and cochlear neurons (4) .   FIG. 1 . Patient demographics. Age, pure tone average (PTA), and word discrimination (WD) for ipsilateral and contralateral ear, tumor size measured in transverse dimension in the cerebellopontine angle (based on most recent MRI scan before surgical excision), and tumor growth rate (based on change in transverse or greatest dimension between the first and last preoperative MRI scans) are shown. There is no statistically significant difference in sex between the good (GH) and poor hearing (PH) group. n = 16 in GH and n = 19 in PH group. Tumor growth rate was available for minority of the tumors (14 of 35) that were followed by serial MRI scans before excision. Detailed information on individual samples is provided in the Supplemental Table 1 FGF2 may be involved in limiting this degeneration in patients with VS that continue to have GH. It is difficult to assess the mechanisms through which FGF2 is asserting its protective role on the cochlear and neuronal cells because no causative studies for HL have been conducted thus far. It may be that FGF2 is blocking a putative neurotoxic or ototoxic substance, interfering with the pathway(s) this substance controls, or easing death from nerve compression. Future studies are needed to delineate these possibilities.
Our finding of high levels of FGF2 secretions by VS associated with GH, combined with the known role of FGF2 as mitogen of VS in vitro (29) and its correlated expression with VS growth in vivo (28) , is consistent with the published reports of large VS that do not cause HL (2, 3, 32) . Our data suggest that FGF2 may mediate tumor growth and hearing level by different mechanisms. If the pathways that lead to tumor growth are divergent from the pathways that modulate hearing, then tumor size or growth rate do not have to correlate with HL. This notion is supported by our cytokine array analysis where levels of well-established growth modulators, such as ERBB, did not correlate with the hearing level, and FGF2 levels did not correlate with tumor size. We could calculate tumor growth rate for only 14 of the 35 tumors because only 40% of the studied patients were followed by serial MRI scans before surgical excision. Within this small subset of tumors, we did not find a significant correlation between tumor growth rate and hearing outcome. This is in contrast to the prior work that found a correlation between high tumor growth rate or large tumor size and poor hearing (33, 34) . These divergent findings are likely not only because of the differences in the sample size but also because of the methodologic or definitional differences, such as the definition of tumor size and hearing loss.
If the putative otoprotective and neuroprotective effects of FGF2 secreted by VS are to be explored in future therapies to preserve hearing in patients with VS, exogenous FGF2 would have to be modified to minimize its growthpromoting potential. Additionally, if FGF2 levels could be measured in the tumor microenvironment, such as by sampling blood serum or cerebrospinal fluid (35Y37),
FIG. 2.
Cytokine array results for 37 proteins studied. Means and SEM are plotted for secretions from VS associated with GH (solid gray columns, n = 11) and PH (backward shaded columns, n = 10) and control GAN (forward shaded columns, n = 7). A, Protein secreted at higher levels in VS associated with GH versus PH. B, Proteins secreted at higher levels in VS associated with PH versus GH. IL1B, IL10, IL12B, 1L13, IL15, IL17, TNFB, and CEA are not shown as they were not significantly secreted by VS or GAN. Statistical significance of *p e 0.05 or **p G 0.01 refers to VS secretions (combining GH and PH) versus GAN secretions.
then FGF2 may be explored as a biomarker to estimate the possibility of the tumor leading to HL and to counsel patients accordingly.
It is reassuring that many proteins previously implicated in pathology of VS and/or HL were found to be significantly elevated in VS compared with control GAN in the present study. Consistent with our study, in which Merlin, the protein encoded by the NF2 gene, was absent in 3 of 21 VS secretions, another study found approximately 23% of tumors to have alterations or loss of both NF2 alleles (38) . Approximately 81% of sporadic schwannomas have mutated NF2 genes with small deletions, and 93% of these mutations result in truncated proteins with defects in all or part of the C-terminus (39) . Because the anti-NF2 antibody used in the cytokine array targets the N-terminus of the protein, we could detect NF2, even if mutated. ERBB2, known to shed in other types of cancers (40) , was also found to be present in 17 of the 21 tumor secretions. Our results are consistent with past work demonstrating ERBB2 in VS, where it plays a role in tumor proliferation and survival (41) . Similarly, platelet-derived growth factor AA (PDGFA) and plateletderived growth factor BB (PDGFB) have been implicated in pathophysiology of VS (27, 42) , and we found both to be present in 13 of 21 VS secretions. We detected a trend, albeit not significant (p = 0.93), for higher PDGFA secretion by VS associated with PH in comparison with GH (Fig. 2) . This trend is consistent with a cDNA microarray analysis published previously (43) . The decrease in significance between the current and previous study may be because we analyzed protein secretions using a larger sample size.
Interestingly, interleukin-1 receptor antagonist (IL1RN) was found to be substantially elevated in tumor secretions associated with GH versus PH, although the result did not meet our criterion for statistical significance (p = 0.10). IL1RN serves to block the receptor for interleukin-1 (IL1) and therefore prevent IL1 signaling. Therapeutic blockade of IL1A and IL1B has been suggested to treat sensorineural HL (9) . Fibronectin-1 (FN1), seen in our previous work as a biomarker for vestibular schwannomas in perilymph (16) , was also found to be significantly upregulated in the VS secretions when compared with GAN secretions (p G 0.001).
FIG. 3.
Analysis of significantly aberrant pathways in VS. Of the 9 proteins that were secreted by VS at significantly different levels than GAN, FGF2, and IL8 met statistical criteria for differential secretion levels between tumors associated with GH versus PH. A, The difference in optical density between GH and PH group is plotted as mean T SEM.*p e 0.05. B, FGF2 and IL8 secretion levels were closely correlated among samples. Each point represents one sample; 2 GH samples and 4 BH samples are not shown as their FGF2 and IL8 levels were within background level.
A larger sample size will be needed in future studies to validate the results of the current study. Moreover, a more elaborate stratification of hearing should be explored in the future (34) , as opposed to a potentially simplistic stratification into 2 categories used in the current study. It is likely that several different mechanisms lead to the spectrum of HL seen with VS and that these mechanisms vary in significance through a tumor's progression for different patients.
CONCLUSION
Sporadic vestibular schwannomas secrete cytokines at substantially higher levels than control great auricular nerves. Fibroblast growth factor 2 is secreted at significantly higher levels by VS with GH versus PH. From past literature, FGF2 is known to protect primary auditory neurons and hair cells from ototoxicity. If future studies establish a causative, rather than a correlative, relationship between FGF2 expression and hearing level in VS, then physicians could use FGF2 as a biomarker for prognosis of the likelihood of HL in patients with VS, which would influence counseling and surgical decision making. In addition, for tumors that are not growing and hence are followed radiographically, modulation of the FGF2 pathways may help maintain patients' hearing.
